US President Donald Trump is preparing to announce a new initiative aimed at reducing prescription drug costs by linking prices paid by the government to lower rates available internationally. The move is expected to be revealed next week, with sources indicating that the plan will involve an executive order focused on medications covered under the Medicare program.

Trump had teased a "very big announcement" earlier in the week, though he did not provide specifics at the time. Multiple sources familiar with the matter have confirmed that the drug pricing proposal is likely to be the centerpiece of the upcoming announcement. However, some uncertainty remains as the exact scope and final details of the initiative are still being refined by administration aides.

The proposed executive order would direct officials to select specific high-cost medications within the Medicare framework and use the administration’s regulatory authority to tie their prices to benchmarks based on international pricing data. The goal is to achieve substantial savings for the government and American consumers, who often pay significantly more for prescription drugs than patients in other developed countries.

The plan underscores the Trump administration’s continued focus on healthcare costs as a key policy issue. If implemented, the pricing initiative could represent a significant shift in how the US government negotiates and regulates drug costs, potentially setting a new precedent for future reforms.

Observers and industry stakeholders are awaiting further details on the plan’s rollout and its potential impact on both domestic and global pharmaceutical markets. As anticipation builds, many will be watching closely to see how the Trump administration balances cost-cutting efforts with the complexities of the healthcare and pharmaceutical sectors.